ICPT Stock Recent News
ICPT LATEST HEADLINES
Intercept (ICPT) gains 12% in the last six months on Ocaliva's positive performance and encouraging pipeline progress.
The 16.4% sales growth of Ocaliva (obeticholic acid or OCA) over the prior year quarter helped lift shares 13.4%. Presentations next week at The Liver Meeting will give a first clinical look at INT-787.
Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Nareg Sagherian - Executive Director, Global IR Jerome Durso - President, CEO & Director Linda Richardson - EVP & Chief Commercial Officer Michelle Berrey - President, Research & Development and Chief Medical Officer Andrew Saik - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co. Ritu Baral - Cowen Steven Seedhouse - Raymond James & Associates Michael Yee - Jefferies Antonio Arce - H.C. Wainwright & Co. Mayank Mamtani - B.
Investors are cheering the drugmaker's Q3 update.
Intercept (ICPT) delivered earnings and revenue surprises of -159.49% and 2.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
MORRISTOWN, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2022 financial results prior to market open on Tuesday, November 1, 2022. The announcement will be followed by a conference call and audio webcast at 8:30 a.m. ET.
Intercept Pharmaceuticals' experimental NASH treatment failed in patients with liver cirrhosis, leading ICPT stock to plummet Friday. The post Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients appeared first on Investor's Business Daily.
Today is a big day for Intercept Pharmaceuticals (NASDAQ: ICPT ). The company just announced the clinical-trial results of Intercept's treatment for NASH cirrhosis.
Poor earnings and a business setback were costly for these companies.